Mantle Cell Lymphoma Video Perspectives

In an interview, Healio spoke with Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program and Staff Physician at the Cleveland Clinic Taussig Cancer Institute, about:

• recent advancements in MCL treatment, specifically the introduction of oral BTK inhibitors and CAR T-cell therapies;
• major risk factors for developing MCL, including factors not included in the MIPI score;
• emerging therapies and drugs for MCL treatment, and the potential utility of non-covalent BTK inhibitors;
• areas of unmet need in MCL, and questions on how to deal with patients who are unsuited for CAR T-cell therapies;
• how he approaches putting together a treatment plan for an MCL patient;
• and how to address quality of life in a patient with MCL, a notoriously aggressive and persistent cancer.